Dr. Mahendiran Dharmasivam has been awarded the 2023 National Breast Cancer Foundation (NBCF) Elaine Henry Fellowship

Dr. Mahendiran Dharmasivam is a research fellow at the Centre for Cancer Cell Biology and Drug Discovery at Griffith University, Australia. Recently, he was awarded the Elaine Henry Fellowship from the National Breast Cancer Foundation for his outstanding contribution and exhibiting the greatest promise as a future leader in breast cancer research.

The Elaine Henry Fellowship is awarded to the pre-eminent researcher from the NBCF Fellowships awarded in 2022 who exhibits the greatest promise as a research leader, this fellowship includes a $20,000 research support fund.

Dr. Dharmasivam's research focuses on the development of novel compounds that can selectively target cancer cells while leaving healthy cells unaffected. His approach to cancer research involves developing small molecules that can bind to cancer cells' specific targets, allowing for the delivery of chemotherapy directly to the tumor site, minimizing the damage to healthy cells. His research has the potential to revolutionize the field of cancer treatment and lead to significant advances in patient outcomes.

Dr. Dharmasivam's extensive research has resulted in numerous publications in high-impact journals. Some of his recent publications include "Designing Tailored Thiosemicarbazones with Bespoke Properties: The Styrene Moiety Imparts Potent Activity, Inhibits Heme Center Oxidation, and Results in a Novel 'Stealth Zinc(II) Complex?," "Thiosemicarbazones reprogram pancreatic cancer bidirectional oncogenic signaling between cancer cells and stellate cells to suppress desmoplasia," and "The thiosemicarbazone, DpC, broadly synergizes with multiple anti-cancer therapeutics and demonstrates temperature- and energy-dependent uptake by tumor cells."

The Elaine Henry Fellowship is a prestigious award that recognizes outstanding scientists' contributions to breast cancer research. The fellowship provides support for early-career researchers to continue their work in the field of breast cancer research. Dr. Dharmasivam's research into the development of small molecules that can selectively target cancer cells has the potential to revolutionize the field of cancer treatment, and the Elaine Henry Fellowship will provide him with the resources to continue his important work.

In conclusion, Dr. Mahendiran Dharmasivam's contributions to cancer research, particularly in the area of breast cancer, are outstanding. His work in developing novel compounds that can selectively target cancer cells has the potential to revolutionize the field of cancer treatment. The Elaine Henry Fellowship recognizes his significant achievements and provides him with the support to continue his research, ultimately leading to significant advances in breast cancer treatment and patient outcomes.